Cockayne Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cockayne syndrome (CS) is a rare, autosomal recessive multisystem disorder caused by mutations in the ERCC8 (CSA) or ERCC6 (CSB) genes, which encode proteins essential for transcription-coupled nucleotide excision repair (TC-NER). The resulting impairment in [DNA damage] repair leads to progressive neurodegeneration, cachectic dwarfism, photosensitivity, and premature aging features. First described by Edward Alfred Cockayne in 1936, the syndrome is one of a small group of nucleotide excision repair (NER) disorders that includes xeroderma pigmentosum and trichothiodystrophy (Cockayne, 1936; Laugel, 2013).
Cockayne syndrome is characterized by postnatal growth failure, progressive microcephaly, and progressive neurological deterioration including [cerebellar] atrophy. The neurodegeneration in CS distinguishes it from other NER-deficient conditions and is thought to result from a combination of defective DNA repair, transcriptional dysregulation, [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, and impaired [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- (Karikkineth et al., 2017).
Cockayne syndrome is a rare disorder with an estimated prevalence of approximately 2-3 per million in Western Europe:
- Incidence: Approximately 1 in 200,000 births in Western Europe (Kleijer et al., 2008)
- Higher prevalence regions: Founder effects have been noted in some isolated populations
- Sex distribution: Affects males and females equally (autosomal recessive)
- Complementation groups: ~80% of patients belong to the CS-B group (ERCC6 mutations); ~20% to the CS-A group (ERCC8 mutations)
- Carrier frequency: Estimated at approximately 1 in 250 in the general population
The disorder has been described in diverse ethnic populations worldwide, though exact prevalence data for many regions remain unavailable (Natale, 2011).
¶ Classification and Clinical Subtypes
Cockayne syndrome is classified into three clinical subtypes based on severity and age of onset:
- Onset: Normal prenatal growth; symptoms appear in the first 1-2 years of life
- Key features: Progressive growth failure, microcephaly, intellectual disability, [cerebellar] ataxia, spasticity, sensorineural hearing loss, and pigmentary retinopathy
- Course: Gradual neurological decline with loss of motor and cognitive milestones
- Life expectancy: Typically 10-20 years, with death from respiratory infection or organ failure
- Genetics: Most commonly associated with ERCC8 (CSA) mutations
- Onset: Symptoms present at birth or within the first weeks of life
- Key features: Severe prenatal growth restriction, congenital cataracts, arthrogryposis, minimal neurological development, and early-onset kyphosis
- Course: Rapid neurological deterioration with minimal developmental milestones achieved
- Life expectancy: Usually less than 5-7 years
- Genetics: More commonly associated with severe ERCC6 (CSB) mutations
- Onset: Later childhood to adolescence
- Key features: Milder growth failure, preserved intellectual function for longer periods, photosensitivity, and slowly progressive neurological symptoms
- Course: Slower progression than Types I and II
- Life expectancy: Can survive into the third decade or beyond
- Genetics: Associated with hypomorphic mutations in either CSA or CSB
(Laugel et al., 2010; Wilson et al., 2016)
¶ Genetics and Molecular Biology
The ERCC8 gene is located on chromosome 5q12.1 and encodes the Cockayne Syndrome A (CSA) protein, a 44 kDa WD-repeat protein that functions as a component of a DDB1-CUL4-based E3 ubiquitin ligase complex (Fischer et al., 2011):
- Structure: Contains 7 WD40 repeats that form a beta-propeller domain
- Function: Acts as a substrate receptor for the CRL4-CSA E3 ubiquitin ligase, targeting specific proteins for ubiquitination during TC-NER
- Key substrates: Ubiquitinates RNA polymerase II (RNAPII) stalled at DNA lesions, facilitating its degradation and allowing access for repair factors
- Pathogenic variants: Over 30 disease-causing mutations identified, including missense, nonsense, splice-site, and frameshift variants
The ERCC6 gene is located on chromosome 10q11.23 and encodes the Cockayne Syndrome B (CSB) protein, a 168 kDa member of the SWI/SNF family of ATP-dependent chromatin remodelers:
- Structure: Contains 7 conserved ATPase motifs characteristic of SWI2/SNF2 DNA-stimulated ATPases
- Function: CSB protein is a multifunctional protein involved in TC-NER, general transcription, chromatin remodeling, and [mitochondrial] maintenance
- Role in TC-NER: Recruited to sites of stalled RNAPII, where it uses ATP hydrolysis to remodel chromatin and facilitate repair factor access
- Pathogenic variants: Over 80 disease-causing mutations identified
(Laugel et al., 2010; Vessoni et al., 2020)
The primary repair pathway disrupted in Cockayne syndrome involves the following steps:
- Lesion recognition: RNA Polymerase II stalls at a DNA lesion during transcription
- CSB recruitment: CSB protein is recruited to the stalled RNAPII complex and remodels chromatin
- CSA-dependent ubiquitination: The CRL4-CSA complex ubiquitinates RNAPII and other factors
- RNAPII backtracking or displacement: The stalled polymerase is moved away from the lesion
- NER factor recruitment: TFIIH, XPA, XPG, and ERCC1-XPF are recruited to excise the damaged strand
- Gap filling: DNA polymerase fills the gap and DNA ligase seals the nick
In CS, defective TC-NER leads to persistent transcription blockage at DNA lesions, triggering [apoptotic] cell death pathways, particularly in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and other postmitotic cells (Hanawalt & Spivak, 2008).
The neuropathology of Cockayne syndrome is distinctive and includes features of both impaired development and neurodegeneration:
- Microcephaly: Progressive brain volume loss, often beginning in the first year
- Brain weight: Typically reduced to 50-75% of age-matched normal
- Cerebral atrophy: Prominent cortical thinning and ventricular enlargement
- [Cerebellar] atrophy: Marked loss of Purkinje cells and granule cells
- Calcifications: Patchy mineralization in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--
- Tigroid demyelination: Patchy loss of myelin with preserved perivascular myelin, creating a characteristic "tigroid" or leopard-skin pattern
- [oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- loss: Reduction in oligodendrocyte density, particularly in severely affected white matter regions
- [Neuronal] loss: Widespread but especially prominent in the [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- (Purkinje and granule cells) and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- Axonal spheroids: Swollen axons indicating disrupted [axonal transport[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects[/mechanisms/[axonal-transport-defects--TEMP--/mechanisms)--FIX--
- Vascular changes: Thickened vessel walls with calcium deposits (calcifying microangiopathy)
- Gliosis: Reactive [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- proliferation throughout affected regions
¶ Retinal and Cochlear Degeneration
- Progressive loss of photoreceptors with pigmentary retinopathy (salt-and-pepper pattern)
- Cochlear degeneration with loss of hair cells and spiral ganglion [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Vestibular dysfunction contributing to balance impairment
(Weidenheim et al., 2009; Koob et al., 2010)
While defective TC-NER is the hallmark molecular defect, research has revealed additional pathogenic mechanisms that contribute to the neurodegeneration and premature aging in CS:
CSB protein has been found to localize to [mitochondria[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- and play roles in mitochondrial DNA (mtDNA) maintenance:
- CS cells show increased [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production
- Impaired mitochondrial membrane potential and respiratory chain function
- Defective mitophagy leading to accumulation of damaged mitochondria
- Reduced NAD+ levels due to hyperactivation of PARP1 by unrepaired DNA damage
(Scheibye-Knudsen et al., 2014)
A critical discovery linking DNA repair defects to neurodegeneration is the NAD+ depletion pathway:
- Unrepaired DNA damage activates poly(ADP-ribose) polymerase 1 (PARP1)
- PARP1 consumes NAD+ to synthesize poly(ADP-ribose) chains
- NAD+ depletion impairs sirtuin function (particularly SIRT1 and SIRT3)
- Reduced sirtuin activity leads to mitochondrial dysfunction and metabolic collapse
- De novo NAD+ biosynthesis is also impaired in CS cells
This pathway represents a potential therapeutic target, as NAD+ supplementation has shown benefit in CS mouse models (Scheibye-Knudsen et al., 2014; Fang et al., 2016).
Beyond their roles in DNA repair, CSA and CSB proteins participate in transcriptional regulation:
- CSB regulates ribosomal RNA transcription and ribosome biogenesis
- Loss of CSB leads to altered gene expression profiles, particularly in [neuronal] differentiation pathways
- Disrupted [epigenetic] regulation including aberrant [DNA methylation[/entities/[dna-methylation[/entities/[dna-methylation[/entities/[dna-methylation--TEMP--/entities)--FIX-- and [histone modifications[/entities/[histone-modifications[/entities/[histone-modifications[/entities/[histone-modifications--TEMP--/entities)--FIX--
- CS cells show defective [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- and impaired clearance of damaged organelles
- Reduced [TFEB[/entities/[tfeb[/entities/[tfeb[/entities/[tfeb--TEMP--/entities)--FIX-- nuclear translocation and [lysosomal] biogenesis
- Accumulation of lipofuscin and other cellular debris, contributing to premature aging phenotype
(Cordisco et al., 2019)
- Cognitive: Progressive intellectual disability; some patients develop normally initially before declining
- Motor: Progressive spasticity, [cerebellar] ataxia, tremor, and contractures
- Peripheral neuropathy: Demyelinating sensorimotor neuropathy
- Seizures: Occur in a minority of patients, more common in severe forms
- Microcephaly: Progressive, often the earliest detectable sign
Ocular involvement is a hallmark of Cockayne syndrome, with progressive retinal and anterior segment changes:
- Pigmentary retinopathy: A progressive "salt-and-pepper" pattern of retinal pigmentation affecting approximately 60% of patients. Fine pigmentary changes begin peripherally and progress centrally, eventually leading to macular atrophy. Ultra-wide-field retinography and autofluorescence imaging reveal diffuse pigment redistribution (Dollfus et al., 2003)
- Electroretinographic abnormalities: Full-field ERG demonstrates progressive cone and rod dysfunction, with marked reduction in both photopic and scotopic responses. Visual function may be preserved despite significant electrophysiological abnormalities in earlier stages (Traboulsi et al., 2019)
- Cataracts: Occur in 15–36% of patients; lens opacities may be nuclear or posterior subcapsular. In Type II (connatal) CS, cataracts can be congenital
- Optic atrophy: Disc pallor is frequently associated with retinal degeneration but may precede retinal changes; contributes to progressive visual loss
- Enophthalmos: Sunken eyes due to loss of periorbital fat, contributing to the characteristic facial appearance
- Other findings: Miotic pupils, decreased or absent tear production, strabismus, nystagmus, photophobia, and narrowed retinal arterioles (Karikkineth et al., 2017; Nance & Berry, 1992)
Auditory impairment is a cardinal feature of Cockayne syndrome, present in over 50% of patients:
- Sensorineural hearing loss: Progressive, beginning with high-frequency loss and advancing to involve speech frequencies. Onset typically occurs in the second year of life for Type I CS. Severity ranges from mild to profound, and progression parallels neurological decline
- Cochlear pathology: Loss of inner and outer hair cells and degeneration of spiral ganglion [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, with preferential loss in the basal (high-frequency) cochlear turn
- Central auditory pathway involvement: Cell loss occurs at multiple sites along the auditory pathway, from the cochlea to the auditory [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, contributing to auditory processing deficits beyond peripheral hearing loss
- NAD+ depletion link: Short-term NAD+ supplementation with nicotinamide riboside prevented hearing loss in CS mouse models (Csb^m/m), linking the NAD+ depletion pathway to auditory pathology (Okur et al., 2020)
- Vestibular dysfunction: Progressive vestibular impairment contributing to balance difficulties and worsening the gait ataxia from [cerebellar] involvement
- Hearing aids: Amplification devices are recommended early to support language and cognitive development (Wilson et al., 2016)
¶ Growth and Skeletal Features
Growth failure is a defining feature of Cockayne syndrome, driven by both metabolic impairment and hormonal dysregulation:
- Postnatal growth failure: Normal birth weight and length, with progressive growth deceleration beginning in the first 1–2 years. Height, weight, and head circumference fall well below the 5th percentile by age 3–5 in Type I CS
- Cachectic dwarfism: Extreme thinness with loss of subcutaneous fat and muscle wasting, resulting in a prematurely aged appearance. Adult height is typically 100–130 cm in Type I CS
- Disproportionate body habitus: Relatively long limbs with large hands and feet compared to the trunk; a long, narrow face and prominent ears
- Bird-like facies: Characteristic craniofacial features include a narrow face, prominent nose and ears, sunken eyes (enophthalmos), micrognathia, and thin skin
- Progressive microcephaly: Brain growth failure leading to an increasingly small head circumference relative to body size
- Kyphosis and joint contractures: Progressive thoracolumbar kyphosis with flexion contractures at hips, knees, and elbows, limiting mobility
- Skeletal changes: Thickened calvarium, sclerotic phalanges, and osteoporosis; vertebral body changes may contribute to spinal deformity
- Dental abnormalities: Severe dental caries, small and malformed teeth, enamel hypoplasia, and early tooth loss (Karikkineth et al., 2017; Natale, 2011)
Cutaneous manifestations reflect both the DNA repair deficiency and the accelerated aging process:
- Photosensitivity: Present in approximately 75% of patients; manifests as facial erythema in a butterfly distribution following sun exposure, due to defective transcription-coupled nucleotide excision repair (TC-NER). While acute sensitivity may diminish over time, chronic changes including telangiectasia, mottled pigmentation, scarring, and cutaneous atrophy persist at photoexposed sites
- Thin, dry skin: Progressive loss of subcutaneous fat and dermal thinning, contributing to the prematurely aged appearance. Skin becomes taut and parchment-like
- Cool, cyanotic extremities: Peripheral vasomotor instability leading to cold hands and feet with cyanotic discoloration; may also present with Raynaud-like symptoms
- Anhidrosis: Decreased or absent sweating, recently identified as a feature particularly in ERCC8 (CSA) patients, contributing to heat intolerance (Zhang et al., 2025)
- Hair changes: Thin, sparse hair; may show premature graying
- Lipodystrophy: Loss of subcutaneous adipose tissue, particularly in the face and extremities (Laugel, 2013)
- Dental caries and enamel hypoplasia
- Hepatomegaly and elevated liver enzymes
- Hypertension
- Anhidrosis (decreased sweating; recently identified as a feature in ERCC8 patients)
(Karikkineth et al., 2017; Zhang et al., 2025)
Diagnosis of Cockayne syndrome is based on the combination of:
- Major criteria (required): Growth failure with microcephaly AND progressive neurological dysfunction
- Supporting features: Photosensitivity, pigmentary retinopathy, sensorineural hearing loss, dental caries, cachectic dwarfism
- MRI: White matter hypomyelination/demyelination, cerebral and [cerebellar] atrophy, [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- calcifications
- CT: Calcifications in the basal ganglia, cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and cerebellum are highly characteristic
- MR Spectroscopy: May show reduced NAA (N-acetylaspartate) and increased choline/creatine ratio
- UV sensitivity assay: Cultured fibroblasts show impaired recovery of RNA synthesis (RRS) after UV irradiation — the gold standard functional test
- Genetic testing: Sequencing of ERCC6 and ERCC8 genes; gene panels for NER disorders
- Prenatal diagnosis: Available via molecular testing when familial mutations are known
¶ Treatment and Management
¶ Current Standard of Care
There is currently no cure for Cockayne syndrome, and management is symptomatic and supportive:
- Feeding support: Gastrostomy tube feeding for patients with swallowing difficulties
- Physical therapy: To manage spasticity and contractures
- Sun protection: Strict UV avoidance and sunscreen for photosensitive patients
- Hearing aids: For sensorineural hearing loss
- Ophthalmological care: Cataract removal, monitoring for retinal degeneration
- Dental care: Regular monitoring and treatment of dental caries
- Seizure management: Antiepileptic medications when needed
Based on the discovery that NAD+ depletion drives pathology in CS:
- Nicotinamide riboside (NR): NAD+ precursor that has shown efficacy in CS mouse models, rescuing [neuronal] phenotypes and extending lifespan (Fang et al., 2016)
- PARP inhibitors: By reducing PARP1-mediated NAD+ consumption, these may preserve cellular NAD+ pools
- AAV-based gene therapy: A 2025 study described development of an AAV vector encoding human CSA under a CBA promoter for Cockayne syndrome type A, demonstrating proof-of-concept in preclinical models (Martin et al., 2025)
- Gene replacement approaches for both CSA and CSB are under development
Enhancing clearance of damaged [mitochondria[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- through [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- represents a therapeutic strategy in CS:
- [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- inhibition: Rapamycin and its analogs (rapalogs) inhibit mTORC1, promoting [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- and [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- to clear dysfunctional mitochondria. Rapamycin treatment has shown benefit in CS cellular models by restoring mitochondrial membrane potential and reducing [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- accumulation
- SIRT1 activation: Because SIRT1 activity is reduced in CS cells due to NAD+ depletion, sirtuin-activating compounds (e.g., resveratrol, SRT1720) may enhance mitochondrial biogenesis through the SIRT1-PGC-1alpha axis
- Urolithin A: A natural mitophagy inducer that promotes PINK1-Parkin-dependent mitophagy; under investigation for age-related mitochondrial dysfunction
- Combined approaches: The NAD+/mitophagy axis may be most effectively targeted through combined NAD+ supplementation and mitophagy enhancement, addressing both the metabolic deficit and organelle quality control failure (Scheibye-Knudsen et al., 2014)
Cockayne syndrome shares mechanistic features with several other neurodegenerative conditions, providing insights into common pathogenic pathways (Scheibye-Knudsen et al., 2014; Karikkineth et al., 2017):
- [DNA damage/repair disorders]: CS belongs to the family of NER disorders alongside xeroderma pigmentosum (XP), trichothiodystrophy (TTD), and UV-sensitive syndrome. XP/CS overlap patients with mutations in XPB, XPD, or XPG show combined features of both disorders
- Premature aging syndromes: Like Werner syndrome, Bloom syndrome, and Hutchinson-Gilford progeria, CS features accelerated aging phenotypes. These progeroid syndromes share disrupted DNA damage response pathways and NAD+ depletion (Fang et al., 2016)
- [Mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--: The role of mitochondrial impairment in CS pathogenesis parallels findings in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and other age-related neurodegenerative diseases, suggesting convergent mitochondrial mechanisms
- NAD+ metabolism: NAD+ depletion as a disease mechanism connects CS to ongoing research in age-related neurodegeneration and metabolic decline. NAD+ supplementation strategies developed for CS (nicotinamide riboside, nicotinamide mononucleotide) are being explored in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- clinical trials (Hikosaka et al., 2024)
- [Cerebellar] neurodegeneration: CS shares features of cerebellar atrophy with [Spinocerebellar Ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX--, [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--, and [ataxia-telangiectasia[/diseases/[ataxia-telangiectasia[/diseases/[ataxia-telangiectasia[/diseases/[ataxia-telangiectasia--TEMP--/diseases)--FIX--, all involving selective vulnerability of [Purkinje cells[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells--TEMP--/cell-types)--FIX-- and granule [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [Purkinje Cells[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells[/cell-types/[purkinje-cells--TEMP--/cell-types)--FIX--
The study of Cockayne Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Cockayne, E.A. (1936]. Dwarfism with retinal atrophy and deafness. Archives of Disease in Childhood, 11(61), 1-8. DOI
- [Laugel, V. (2013]. Cockayne syndrome: The expanding clinical and mutational spectrum. Mechanisms of Ageing and Development, 134(5-6), 161-170. PubMed)
- [Karikkineth, A.C., et al. (2017]. Cockayne syndrome: Clinical features, model systems and pathways. Mechanisms of Ageing and Development, 134, 161-170. DOI
- [Kleijer, W.J., et al. (2008]. Incidence of DNA repair deficiency disorders in Western Europe. DNA Repair, 7(5), 744-750. DOI
- [Natale, V. (2011]. A comprehensive description of the severity groups in Cockayne syndrome. American Journal of Medical Genetics Part A, 155(5), 1081-1095. PubMed)
- [Laugel, V., et al. (2010]. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. Journal of Medical Genetics, 47(4), 289-298. DOI
- [Wilson, B.T., et al. (2016]. The Cockayne Syndrome Natural History (CoSyNH) study. Journal of Medical Genetics, 53(8), 527-545. PubMed)
- [Vessoni, A.T., et al. (2020]. Cockayne Syndrome: The many challenges and approaches to understand a multifaceted disease. Mechanisms of Ageing and Development, 186, 111365. DOI
- [Hanawalt, P.C. & Spivak, G. (2008]. Transcription-coupled DNA repair: Two decades of progress and surprises. Nature Reviews Molecular Cell Biology, 9(12), 958-970. DOI
- [Weidenheim, K.M., et al. (2009]. Neuropathology of Cockayne syndrome: Evidence for impaired development, premature aging, and neurodegeneration. Mechanisms of Ageing and Development, 130(9), 619-636. DOI
- [Koob, M., et al. (2010]. Neuroimaging in Cockayne Syndrome. Human Molecular Genetics, 19(15), 3121-3129. DOI
- [Scheibye-Knudsen, M., et al. (2014]. A high-fat diet and NAD+ activate Sirt1 to rescue premature aging in Cockayne syndrome. Cell Reports, 9(4), 1202-1209. DOI
- [Fang, E.F., et al. (2016]. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. PNAS, 113(40), E5706-E5715. DOI
- [Cordisco, S., et al. (2019]. Cockayne Syndrome type A protein protects primary human keratinocytes from senescence. Cell Death & Differentiation, 26(10), 2005-2019. DOI
- [Martin, C.L., et al. (2025]. AAV gene therapy for Cockayne syndrome. bioRxiv. DOI: 10.1101/2025.06.06.658349)
- [Zhang, Y., et al. (2025]. Clinical and genetic analysis of ERCC8-Related Cockayne syndrome. Frontiers in Genetics, 16, 1591551. DOI: 10.3389/fgene.2025.1591551)
- [Dollfus, H., et al. (1992]. Ocular findings in Cockayne syndrome. Journal of Pediatric Ophthalmology and Strabismus, 29(5), 282-289. PubMed)
- [Traboulsi, E.I., et al. (2019]. Cockayne syndrome in adults: complete retinal dysfunction exploration. Ophthalmic Genetics, 40(2), 123-130. PubMed)
- [Okur, M.N., et al. (2020]. Short-term NAD+ supplementation prevents hearing loss in mouse models of Cockayne syndrome. npj Aging, 6, 1. DOI: 10.1038/s41514-019-0040-z)
- [Fischer, E.S., et al. (2011]. The molecular basis of CRL4-DDB1-CSA ubiquitin ligase architecture. Cell, 147(5), 1024-1039. DOI
- [Hikosaka, K., et al. (2024]. Supplementation with nicotinamide limits accelerated aging in affected individuals with Cockayne syndrome. Aging, 16(24), 11492-11508. PubMed)